Payment overview · 2025
General Payments
$3,739.16
146 reported records · 44 companies
Healthcare provider profile · identity verified
Kathy Sam, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology · HOUSTON, TX · NPI 1427203819
Verified facts
What the public records show
CMS Open Payments records show Kathy Sam, M.D. received $3,739.16 in general payments during 2025 across 146 reported records.
AstraZeneca Pharmaceuticals LP accounted for 9.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 70 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Calquence, Ibrance, Imbruvica, Jakafi, Keytruda, Lynparza, Orgovyx, Tukysa, Verzenio, Xtandi.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 15599 records involving 6881 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Imbruvica by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBRANCE as an associated drug or biological on 54 records involving 52 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Ibrance by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORGOVYX as an associated drug or biological on 29 records involving 26 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Orgovyx by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TUKYSA as an associated drug or biological on 5271 records involving 2869 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tukysa by this doctor in 2024.
ARRAY BIOPHARMA INC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 98 records involving 88 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Xtandi by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xtandi as an associated drug or biological on 11345 records involving 5418 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Xtandi by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported CALQUENCE as an associated drug or biological on 8404 records involving 3935 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Calquence by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYNPARZA as an associated drug or biological on 9531 records involving 5030 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lynparza by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TAGRISSO as an associated drug or biological on 5285 records involving 2776 distinct recipient NPIs. Public Medicare Part D data also shows 58 claims for Tagrisso by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Eliquis by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Eliquis by this doctor in 2024.
Incyte Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JAKAFI as an associated drug or biological on 14854 records involving 6477 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Jakafi by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IMBRUVICA as an associated drug or biological on 47 records involving 33 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Imbruvica by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERZENIO as an associated drug or biological on 9278 records involving 4763 distinct recipient NPIs. Public Medicare Part D data also shows 90 claims for Verzenio by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported KEYTRUDA as an associated drug or biological on 46588 records involving 15767 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Keytruda by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LYNPARZA as an associated drug or biological on 10903 records involving 6595 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Lynparza by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROMACTA as an associated drug or biological on 47 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Promacta by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported IBRANCE as an associated drug or biological on 11505 records involving 4934 distinct recipient NPIs. Public Medicare Part D data also shows 64 claims for Ibrance by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORGOVYX as an associated drug or biological on 16373 records involving 6981 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Orgovyx by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TUKYSA as an associated drug or biological on 10028 records involving 4442 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Tukysa by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XTANDI as an associated drug or biological on 19368 records involving 7657 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Xtandi by this doctor in 2024.
Sumitomo Pharma America, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORGOVYX as an associated drug or biological on 17129 records involving 6223 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Orgovyx by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $351.62 | 9.4% | 13 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $312.90 | 8.4% | 4 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $211.12 | 5.7% | 7 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $200.51 | 5.4% | 9 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $179.75 | 4.8% | 7 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $170.60 | 4.6% | 7 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $153.82 | 4.1% | 8 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $146.12 | 3.9% | 6 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $116.78 | 3.1% | 5 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $107.73 | 2.9% | 4 | 2025 |
| Incyte Corporation | Unresolved — no canonical attribution shown | $101.68 | 2.7% | 5 | 2025 |
| Gilead Sciences, Inc. | Unresolved — no canonical attribution shown | $100.22 | 2.7% | 5 | 2025 |
| Kite Pharma, Inc. | Unresolved — no canonical attribution shown | $99.50 | 2.7% | 4 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $98.43 | 2.6% | 4 | 2025 |
| Takeda Pharmaceuticals U.S.A., Inc. | Unresolved — no canonical attribution shown | $94.02 | 2.5% | 4 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $93.80 | 2.5% | 3 | 2025 |
| Deciphera Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $89.41 | 2.4% | 3 | 2025 |
| BeOne Medicines USA, Inc. | Unresolved — no canonical attribution shown | $85.32 | 2.3% | 4 | 2025 |
| Geron Corporation | Unresolved — no canonical attribution shown | $81.71 | 2.2% | 3 | 2025 |
| ARRAY BIOPHARMA INC | Unresolved — no canonical attribution shown | $79.19 | 2.1% | 3 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $66.79 | 1.8% | 4 | 2025 |
| Eisai Inc. | Unresolved — no canonical attribution shown | $61.72 | 1.6% | 2 | 2025 |
| Rigel Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $59.86 | 1.6% | 2 | 2025 |
| PUMA BIOTECHNOLOGY, INC. | Unresolved — no canonical attribution shown | $59.29 | 1.6% | 3 | 2025 |
| Syndax Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $50.19 | 1.3% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $49.56 | 1.3% | 2 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $46.50 | 1.2% | 2 | 2025 |
| Exelixis Inc. | Unresolved — no canonical attribution shown | $39.85 | 1.1% | 2 | 2025 |
| SOBI, INC | Unresolved — no canonical attribution shown | $38.83 | 1.0% | 1 | 2025 |
| Karyopharm Therapeutics Inc. | Unresolved — no canonical attribution shown | $37.84 | 1.0% | 2 | 2025 |
| EMD Serono, Inc. | Unresolved — no canonical attribution shown | $34.65 | 0.9% | 1 | 2025 |
| Stemline Therapeutics Inc. | Unresolved — no canonical attribution shown | $30.55 | 0.8% | 1 | 2025 |
| SpringWorks Therapeutics, Inc. | Unresolved — no canonical attribution shown | $29.46 | 0.8% | 1 | 2025 |
| Apellis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $29.27 | 0.8% | 1 | 2025 |
| Spectrum Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $29.01 | 0.8% | 1 | 2025 |
| Ipsen Biopharmaceuticals, Inc | Unresolved — no canonical attribution shown | $27.76 | 0.7% | 1 | 2025 |
| Amneal Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $27.11 | 0.7% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $26.81 | 0.7% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $24.99 | 0.7% | 1 | 2025 |
| ERBE USA Inc | Unresolved — no canonical attribution shown | $22.00 | 0.6% | 2 | 2025 |
| SERVIER PHARMACEUTICALS LLC | Unresolved — no canonical attribution shown | $21.20 | 0.6% | 1 | 2025 |
| TAIHO ONCOLOGY, INC. | Unresolved — no canonical attribution shown | $19.28 | 0.5% | 1 | 2025 |
| Cycle Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $16.77 | 0.5% | 1 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $15.64 | 0.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $3,503.96 | 145 |
| Grant | $235.20 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ELAHERE Normalized: elahere |
Drug | ABBVIE INC. | $235.20 | 1 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $211.12 | 7 | 2025 |
Source payment records
|
|||||
| KEYTRUDA Normalized: keytruda |
Biological | Merck Sharp & Dohme LLC | $170.60 | 7 | 2025 |
Source payment records
|
|||||
| JAYPIRCA Normalized: jaypirca |
Drug | Lilly USA, LLC | $153.82 | 8 | 2025 |
Source payment records
|
|||||
| VERZENIO Normalized: verzenio |
Drug | Lilly USA, LLC | $153.82 | 8 | 2025 |
Source payment records
|
|||||
| ENHERTU Normalized: enhertu |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Daiichi Sankyo Inc. | $130.33 | 5 | 2025 |
Source payment records
|
|||||
| TUKYSA Normalized: tukysa |
Drug | ARRAY BIOPHARMA INC, PFIZER INC. | $110.05 | 4 | 2025 |
Source payment records
|
|||||
| PADCEV Normalized: padcev |
Biological, Drug | Astellas Pharma US Inc, PFIZER INC. | $106.19 | 5 | 2025 |
Source payment records
|
|||||
| IMFINZI Normalized: imfinzi |
Biological | AstraZeneca Pharmaceuticals LP | $105.67 | 4 | 2025 |
Source payment records
|
|||||
| OPDIVO Normalized: opdivo |
Biological | E.R. Squibb & Sons, L.L.C. | $103.80 | 4 | 2025 |
Source payment records
|
|||||
| Trodelvy Normalized: trodelvy |
Drug | Gilead Sciences, Inc. | $100.22 | 5 | 2025 |
Source payment records
|
|||||
| Yescarta Normalized: yescarta |
Drug | Kite Pharma, Inc. | $99.50 | 4 | 2025 |
Source payment records
|
|||||
| ZEPZELCA Normalized: zepzelca |
Drug | JAZZ PHARMACEUTICALS INC. | $93.80 | 3 | 2025 |
Source payment records
|
|||||
| QINLOCK Normalized: qinlock |
Drug | Deciphera Pharmaceuticals Inc. | $89.41 | 3 | 2025 |
Source payment records
|
|||||
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $87.79 | 4 | 2025 |
Source payment records
|
|||||
| OJJAARA Normalized: ojjaara |
Drug | GlaxoSmithKline, LLC. | $85.25 | 4 | 2025 |
Source payment records
|
|||||
| RYTELO Normalized: rytelo |
Drug | Geron Corporation | $81.71 | 3 | 2025 |
Source payment records
|
|||||
| ORGOVYX Normalized: orgovyx |
Drug | PFIZER INC., Sumitomo Pharma America, Inc. | $80.66 | 3 | 2025 |
Source payment records
|
|||||
| BRAFTOVI Normalized: braftovi |
Drug | ARRAY BIOPHARMA INC | $79.19 | 3 | 2025 |
Source payment records
|
|||||
| MEKTOVI Normalized: mektovi |
Drug | ARRAY BIOPHARMA INC | $79.19 | 3 | 2025 |
Source payment records
|
|||||
| REBLOZYL Normalized: reblozyl |
Biological | Celgene Corporation | $73.77 | 3 | 2025 |
Source payment records
|
|||||
| XTANDI Normalized: xtandi |
Drug | Astellas Pharma US Inc, PFIZER INC. | $69.64 | 3 | 2025 |
Source payment records
|
|||||
| JAKAFI Normalized: jakafi |
Drug | Incyte Corporation | $68.40 | 3 | 2025 |
Source payment records
|
|||||
| NIKTIMVO Normalized: niktimvo |
Drug | Incyte Corporation | $68.40 | 3 | 2025 |
Source payment records
|
|||||
| OPDUALAG Normalized: opdualag |
Drug | Celgene Corporation, E.R. Squibb & Sons, L.L.C. | $66.90 | 3 | 2025 |
Source payment records
|
|||||
| CALQUENCE Normalized: calquence |
Drug | AstraZeneca Pharmaceuticals LP | $64.21 | 2 | 2025 |
Source payment records
|
|||||
| Lenvima Normalized: lenvima |
Drug | Eisai Inc. | $61.72 | 2 | 2025 |
Source payment records
|
|||||
| JEMPERLI Normalized: jemperli |
Biological | GlaxoSmithKline, LLC. | $60.87 | 2 | 2025 |
Source payment records
|
|||||
| ZEJULA Normalized: zejula |
Drug | GlaxoSmithKline, LLC. | $60.87 | 2 | 2025 |
Source payment records
|
|||||
| LYNPARZA Normalized: lynparza |
Biological, Drug | AstraZeneca Pharmaceuticals LP, Merck Sharp & Dohme LLC | $60.79 | 2 | 2025 |
Source payment records
|
|||||
| Gavreto Normalized: gavreto |
Drug | Rigel Pharmaceuticals, Inc. | $59.86 | 2 | 2025 |
Source payment records
|
|||||
| Rezlidhia Normalized: rezlidhia |
Drug | Rigel Pharmaceuticals, Inc. | $59.86 | 2 | 2025 |
Source payment records
|
|||||
| TAVALISSE Normalized: tavalisse |
Drug | Rigel Pharmaceuticals, Inc. | $59.86 | 2 | 2025 |
Source payment records
|
|||||
| NERLYNX Normalized: nerlynx |
Drug | PUMA BIOTECHNOLOGY, INC. | $59.29 | 3 | 2025 |
Source payment records
|
|||||
| ROMVIMZA Normalized: romvimza |
Drug | Deciphera Pharmaceuticals Inc. | $56.98 | 2 | 2025 |
Source payment records
|
|||||
| BRUKINSA Normalized: brukinsa |
Drug | BeOne Medicines USA, Inc. | $56.09 | 3 | 2025 |
Source payment records
|
|||||
| TALZENNA Normalized: talzenna |
Drug | PFIZER INC. | $55.67 | 2 | 2025 |
Source payment records
|
|||||
| IBRANCE Normalized: ibrance |
Drug | PFIZER INC. | $54.09 | 2 | 2025 |
Source payment records
|
|||||
| Itovebi Normalized: itovebi |
Biological | Genentech USA, Inc. | $49.56 | 2 | 2025 |
Source payment records
|
|||||
| NINLARO Normalized: ninlaro |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $47.56 | 2 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $46.50 | 2 | 2025 |
Source payment records
|
|||||
| FRUZAQLA Normalized: fruzaqla |
Drug | Takeda Pharmaceuticals U.S.A., Inc. | $46.46 | 2 | 2025 |
Source payment records
|
|||||
| CABOMETYX Normalized: cabometyx |
Drug | Exelixis Inc. | $39.85 | 2 | 2025 |
Source payment records
|
|||||
| Vonjo Normalized: vonjo |
Drug | SOBI, INC | $38.83 | 1 | 2025 |
Source payment records
|
|||||
| XPOVIO Normalized: xpovio |
Drug | Karyopharm Therapeutics Inc. | $37.84 | 2 | 2025 |
Source payment records
|
|||||
| MONJUVI Normalized: monjuvi |
Drug | Incyte Corporation | $33.28 | 2 | 2025 |
Source payment records
|
|||||
| TGCT Normalized: tgct |
Drug | Deciphera Pharmaceuticals Inc. | $32.43 | 1 | 2025 |
Source payment records
|
|||||
| Orserdu Normalized: orserdu |
Drug | Stemline Therapeutics Inc. | $30.55 | 1 | 2025 |
Source payment records
|
|||||
| DATROWAY Normalized: datroway |
Drug | Daiichi Sankyo Inc. | $29.86 | 1 | 2025 |
Source payment records
|
|||||
| GOMEKLI Normalized: gomekli |
Drug | SpringWorks Therapeutics, Inc. | $29.46 | 1 | 2025 |
Source payment records
|
|||||
| TEVIMBRA Normalized: tevimbra |
Drug | BeOne Medicines USA, Inc. | $29.23 | 1 | 2025 |
Source payment records
|
|||||
| ROLVEDON Normalized: rolvedon |
Drug | Spectrum Pharmaceuticals Inc. | $29.01 | 1 | 2025 |
Source payment records
|
|||||
| Fabhalta Normalized: fabhalta |
Drug | Novartis Pharmaceuticals Corporation | $28.99 | 1 | 2025 |
Source payment records
|
|||||
| Onivyde Normalized: onivyde |
Drug | Ipsen Biopharmaceuticals, Inc | $27.76 | 1 | 2025 |
Source payment records
|
|||||
| EPKINLY Normalized: epkinly |
Drug | ABBVIE INC. | $27.45 | 1 | 2025 |
Source payment records
|
|||||
| IMBRUVICA Normalized: imbruvica |
Drug | ABBVIE INC. | $27.45 | 1 | 2025 |
Source payment records
|
|||||
| EMRELIS Normalized: emrelis |
Drug | ABBVIE INC. | $27.19 | 1 | 2025 |
Source payment records
|
|||||
| ALYMSYS Normalized: alymsys |
Drug | Amneal Pharmaceuticals LLC | $27.11 | 2 | 2025 |
Source payment records
|
|||||
| SARCLISA Normalized: sarclisa |
Biological | GENZYME CORPORATION | $26.81 | 1 | 2025 |
Source payment records
|
|||||
| KEYTRUDA QLEX Normalized: keytruda qlex |
Biological | Merck Sharp & Dohme LLC | $24.13 | 1 | 2025 |
Source payment records
|
|||||
| LORBRENA Normalized: lorbrena |
Drug | ARRAY BIOPHARMA INC | $23.23 | 1 | 2025 |
Source payment records
|
|||||
| VENCLEXTA Normalized: venclexta |
Drug | ABBVIE INC. | $23.06 | 1 | 2025 |
Source payment records
|
|||||
| ERBECryo2 Normalized: erbecryo2 |
Device | ERBE USA Inc | $22.00 | 2 | 2025 |
Source payment records
|
|||||
| Tibsovo Normalized: tibsovo |
Drug | SERVIER PHARMACEUTICALS LLC | $21.20 | 1 | 2025 |
Source payment records
|
|||||
| BLENREP Normalized: blenrep |
Biological | GlaxoSmithKline, LLC. | $19.97 | 1 | 2025 |
Source payment records
|
|||||
| INQOVI Normalized: inqovi |
Drug | TAIHO ONCOLOGY, INC. | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| LONSURF Normalized: lonsurf |
Drug | TAIHO ONCOLOGY, INC. | $19.28 | 1 | 2025 |
Source payment records
|
|||||
| Phyrago Normalized: phyrago |
Drug | Cycle Pharmaceuticals Inc | $16.77 | 1 | 2025 |
Source payment records
|
|||||
| Vyloy Normalized: vyloy |
Drug | Astellas Pharma US Inc | $16.62 | 1 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $15.64 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| CALQUENCE calquence |
2025 | Calquence | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| IBRANCE ibrance |
2025 | Ibrance | 2024 | 64 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| IMBRUVICA imbruvica |
2025 | Imbruvica | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| JAKAFI jakafi |
2025 | Jakafi | 2024 | 19 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| KEYTRUDA keytruda |
2025 | Keytruda | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LYNPARZA lynparza |
2025 | Lynparza | 2024 | 16 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ORGOVYX orgovyx |
2025 | Orgovyx | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TUKYSA tukysa |
2025 | Tukysa | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| VERZENIO verzenio |
2025 | Verzenio | 2024 | 90 | exact normalized | Medicare Part D |
| XTANDI xtandi |
2025 | Xtandi | 2024 | 28 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 15599 supporting records · 6881 recipient NPIs · example record 1201352838 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | IBRANCE open payments reported associated product |
CMS Open Payments — General Payments 54 supporting records · 52 recipient NPIs · example record 1228804288 |
Ibrance · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | ORGOVYX open payments reported associated product |
CMS Open Payments — General Payments 29 supporting records · 26 recipient NPIs · example record 1228888885 |
Orgovyx · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | TUKYSA open payments reported associated product |
CMS Open Payments — General Payments 5271 supporting records · 2869 recipient NPIs · example record 1228794645 |
Tukysa · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ARRAY BIOPHARMA INC Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 98 supporting records · 88 recipient NPIs · example record 1228800820 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Xtandi open payments reported associated product |
CMS Open Payments — General Payments 11345 supporting records · 5418 recipient NPIs · example record 1238560686 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | CALQUENCE open payments reported associated product |
CMS Open Payments — General Payments 8404 supporting records · 3935 recipient NPIs · example record 1206131382 |
Calquence · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | LYNPARZA open payments reported associated product |
CMS Open Payments — General Payments 9531 supporting records · 5030 recipient NPIs · example record 1206131376 |
Lynparza · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TAGRISSO open payments reported associated product |
CMS Open Payments — General Payments 5285 supporting records · 2776 recipient NPIs · example record 1206131546 |
Tagrisso · 2024 Exact normalized brand match · 1 Part D row |
58 | suppressed by CMS |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
105 | 21 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
105 | 21 |
| Incyte Corporation Exact reporting entity; no affiliate inference |
2025 | JAKAFI open payments reported associated product |
CMS Open Payments — General Payments 14854 supporting records · 6477 recipient NPIs · example record 1225959940 |
Jakafi · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | IMBRUVICA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 33 recipient NPIs · example record 1174328453 |
Imbruvica · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | VERZENIO open payments reported associated product |
CMS Open Payments — General Payments 9278 supporting records · 4763 recipient NPIs · example record 1186464449 |
Verzenio · 2024 Exact normalized brand match · 1 Part D row |
90 | 13 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | KEYTRUDA open payments reported associated product |
CMS Open Payments — General Payments 46588 supporting records · 15767 recipient NPIs · example record 1237992210 |
Keytruda · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | LYNPARZA open payments reported associated product |
CMS Open Payments — General Payments 10903 supporting records · 6595 recipient NPIs · example record 1237992238 |
Lynparza · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | PROMACTA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 47 recipient NPIs · example record 1200028032 |
Promacta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
105 | 21 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | IBRANCE open payments reported associated product |
CMS Open Payments — General Payments 11505 supporting records · 4934 recipient NPIs · example record 1228794164 |
Ibrance · 2024 Exact normalized brand match · 1 Part D row |
64 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ORGOVYX open payments reported associated product |
CMS Open Payments — General Payments 16373 supporting records · 6981 recipient NPIs · example record 1228794230 |
Orgovyx · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | TUKYSA open payments reported associated product |
CMS Open Payments — General Payments 10028 supporting records · 4442 recipient NPIs · example record 1228794329 |
Tukysa · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XTANDI open payments reported associated product |
CMS Open Payments — General Payments 19368 supporting records · 7657 recipient NPIs · example record 1228794230 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Sumitomo Pharma America, Inc. Exact reporting entity; no affiliate inference |
2025 | ORGOVYX open payments reported associated product |
CMS Open Payments — General Payments 17129 supporting records · 6223 recipient NPIs · example record 1176593507 |
Orgovyx · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Letrozole | Letrozole | 213 | 76 |
| Eliquis | Apixaban | 105 | 21 |
| Anastrozole | Anastrozole | 98 | 31 |
| Dexamethasone | Dexamethasone | 92 | 49 |
| Ondansetron Odt | Ondansetron | 90 | 68 |
| Verzenio | Abemaciclib | 90 | 13 |
| Prednisone | Prednisone | 83 | 22 |
| Procrit | Epoetin Alfa | 73 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 72 | 24 |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 72 | 58 |
| Levothyroxine Sodium | Levothyroxine Sodium | 67 | 19 |
| Ibrance | Palbociclib | 64 | suppressed |
| Aranesp | Darbepoetin Alfa In Polysorbat | 63 | 16 |
| Granisetron Hcl | Granisetron Hcl | 60 | 49 |
| Gabapentin | Gabapentin | 59 | 16 |
| Warfarin Sodium | Warfarin Sodium | 59 | suppressed |
| Tagrisso | Osimertinib Mesylate | 58 | suppressed |
| Loperamide | Loperamide Hcl | 51 | 37 |
| Revlimid | Lenalidomide | 48 | suppressed |
| Abiraterone Acetate | Abiraterone Acetate | 46 | suppressed |
| Aprepitant | Aprepitant | 42 | suppressed |
| Tamoxifen Citrate | Tamoxifen Citrate | 40 | 14 |
| Lenalidomide | Lenalidomide | 39 | suppressed |
| Imbruvica | Ibrutinib | 38 | suppressed |
| Retacrit | Epoetin Alfa-Epbx | 38 | suppressed |
| Olanzapine | Olanzapine | 33 | 18 |
| Hydroxyurea | Hydroxyurea | 32 | 12 |
| Famciclovir | Famciclovir | 30 | 11 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 30 | 30 |
| Neulasta | Pegfilgrastim | 29 | suppressed |
| Exemestane | Exemestane | 28 | suppressed |
| Orgovyx | Relugolix | 28 | suppressed |
| Xtandi | Enzalutamide | 28 | suppressed |
| Hydrocortisone | Hydrocortisone | 27 | 11 |
| Promethazine Hcl | Promethazine Hcl | 26 | 20 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 26 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 25 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 24 | 11 |
| Promacta | Eltrombopag Olamine | 20 | suppressed |
| Jakafi | Ruxolitinib Phosphate | 19 | suppressed |
| Fulvestrant | Fulvestrant | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 17 | suppressed |
| Sps | Sodium Polystyrene Sulfon/Sorb | 17 | suppressed |
| Allopurinol | Allopurinol | 16 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 16 | 14 |
| Lynparza | Olaparib | 16 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 16 | 12 |
| Omeprazole | Omeprazole | 15 | 11 |
| Keytruda | Pembrolizumab | 14 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 14 | suppressed |
| Potassium Chloride | Potassium Chloride | 13 | 11 |
| Calquence | Acalabrutinib Maleate | 12 | suppressed |
| Neulasta Onpro | Pegfilgrastim | 12 | suppressed |
| Tukysa | Tucatinib | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Atovaquone | Atovaquone | 11 | suppressed |
| Cimetidine | Cimetidine | 11 | suppressed |
| Clindamycin Phosphate | Clindamycin Phosphate | 11 | suppressed |
| Levetiracetam | Levetiracetam | 11 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 11 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $3,739.16 · 146 records | AstraZeneca Pharmaceuticals LP | ALYMSYS, BESREMI, BLENREP, BRAFTOVI, BRUKINSA, CABOMETYX, CALQUENCE, DATROWAY, ELAHERE, EMRELIS, ENHERTU, EPKINLY, ERBECryo2, FRUZAQLA, Fabhalta, GOMEKLI, Gavreto, IBRANCE, IMBRUVICA, IMFINZI, INQOVI, Itovebi, JAKAFI, JAYPIRCA, JEMPERLI, KEYTRUDA, KEYTRUDA QLEX, KISQALI, LONSURF, LORBRENA, LYNPARZA, Lenvima, MEKTOVI, MONJUVI, MONOFERRIC, NERLYNX, NIKTIMVO, NINLARO, OJJAARA, OPDIVO, OPDUALAG, ORGOVYX, Onivyde, Orserdu, PADCEV, Phyrago, QINLOCK, REBLOZYL, ROLVEDON, ROMVIMZA, RYBREVANT, RYTELO, Rezlidhia, SARCLISA, TALZENNA, TAVALISSE, TEVIMBRA, TGCT, TUKYSA, Tibsovo, Trodelvy, VENCLEXTA, VERZENIO, Vonjo, Vyloy, XPOVIO, XTANDI, Yescarta, ZEJULA, ZEPZELCA | 23 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Calquence play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error